NS
CRSP icon

NBC Securities’s CRISPR Therapeutics CRSP Stock Holding History

NBC Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Sell
1,150
-61
-5% -$3.21K ﹤0.01% 1220
2026
Q1 		$57.6K Buy
1,211
+215
+22% +$11.3K ﹤0.01% 1265
2025
Q4 		$52.2K Buy
996
+88
+10% +$5.27K ﹤0.01% 1337
2025
Q3 		$58.8K Sell
908
-656
-42% -$37.7K ﹤0.01% 1267
2025
Q2 		$76K Hold
1,564
– – 0.01% 1163
2025
Q1 		$53K Buy
1,564
+1,563
+156,300% +$66.3K ﹤0.01% 1145
2024
Q4 		$62 Sell
1
-956
-100% -$45.1K 0.01% 1006
2024
Q3 		$44K Buy
957
+119
+14% +$6.04K ﹤0.01% 1218
2024
Q2 		$45K Buy
838
+230
+38% +$13.3K ﹤0.01% 1176
2024
Q1 		$41K Buy
608
+438
+258% +$31.4K ﹤0.01% 1192
2023
Q4 		$10K Sell
170
-100
-37% -$5.53K ﹤0.01% 1693
2023
Q3 		$12K Buy
+270
New +$13.9K ﹤0.01% 1642

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NBC Securities's CRSP Position: Q2 2026 in Review

NBC Securities reduced its CRISPR Therapeutics (CRSP) stake by 5% in Q2 2026, selling an estimated $3.21K and leaving 1,150 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

NBC Securities first reported a position in CRSP in Q3 2023 and has held it in 12 quarters since. The position peaked at $76K in Q2 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • NBC Securities held 1,150 shares of CRISPR Therapeutics worth $62.7K as of Q2 2026.
  • NBC Securities sold 61 CRISPR Therapeutics shares in Q2 2026, an estimated $3.21K.
  • CRISPR Therapeutics made up ﹤0.01% of NBC Securities's portfolio in Q2 2026, its #1220 holding.
  • NBC Securities first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • NBC Securities's CRISPR Therapeutics position peaked at $76K in Q2 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.